The effect of gonadotrophin releasing hormone analogue on height prognosis in growth hormone deficiency and normal puberty
β Scribed by R. Stanhope; C. G. D. Brook
- Publisher
- Springer
- Year
- 1988
- Tongue
- English
- Weight
- 253 KB
- Volume
- 148
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
β¦ Synopsis
We have treated seven pubertal children, five (three female, two male) with growth hormone deficiency and two (one female, one male) with constitutional short stature with intranasal (D-Serine6) gonadotrophin releasing hormone (GnRH) analogue (Buserelin) for a mean of 0.84 years (range, 0.5-1.3). Treatment was successful in arresting pubertal development but there was no improvement in final height prognosis.
π SIMILAR VOLUMES
The shortened analogue of growth hormone releasing factor (GRF) Ro 23-7861 (1) has a molecular weight of 3929 daltons [equivalent to GRF (1-29)] and is more potent than the endogenous GRF (1-44). The in vitro hairless guinea pig model and vertical and horizontal diffusion cell assemblies were used t
The effect of glucose on insulin release and the influence of glibenclamide on linear growth were determined in five growth hormone (STH) deficient children who were treated with human growth hormone. It was found that the administration of 5 I.U. of human growth hormone twice a week improved the de